報價延遲最少15分鐘:2026/04/21 22:31 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.8235 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.80/-0.59
|
|
企業價值
94.22M
|
| 資產負債 |
|
每股賬面淨值
0.69
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
190.00K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD). |
